Schaltbau has launched the Eddicy R300 high-voltage relay, extending its proven railway technology to industrial testing applications. The relay handles up to 10,000V with advanced safety features for demanding test environments.
Major tech companies posted impressive earnings but faced stock declines as massive AI spending collided with investor expectations. The market’s reaction signals a potential turning point in the AI investment cycle.
The WinAmp Community Update Project releases version 1.99.41.22960 with significant stability improvements and modern features. This community-driven effort keeps the legendary media player relevant for today’s users.
Researchers have uncovered a remarkable vulnerability in one of medicine’s most drug-resistant bacteria. By exploiting the pathogen’s own defense mechanisms, they’ve created a compound that becomes more lethal as the bacteria tries to fight it off.
While AI CEOs make apocalyptic predictions and spiritual claims, the engineers building the technology are urging everyone to calm down. The gap between hype and reality has never been wider.
In an age of AI summaries and curated content, the most valuable business skill might be embracing noise rather than eliminating it. Learn why information chaos drives better decisions.
The legendary “cable cowboy” John Malone is stepping down from his chairman roles at Liberty Global and Liberty Media. At 84, Malone’s departure marks the end of an era in telecommunications leadership.
U.S. rare earth miners saw immediate stock gains after China agreed to delay export restrictions. The temporary reprieve highlights ongoing vulnerabilities in critical mineral supply chains that power everything from EVs to defense systems.
The Trump administration has halved additional tariffs on Chinese imports from 20% to 10%, providing immediate relief to Apple and other US companies. The move follows volatile trade negotiations that saw tariffs briefly exceed 100%.
Life science giant Thermo Fisher Scientific makes a massive $9.4 billion move into clinical trial software. The acquisition of Clario represents a strategic pivot toward digital endpoints and AI-powered drug development analytics.
